Month: July 2021

In the 2nd quarter of 2021, the revenue of AS Ekspress Grupp totalled EUR 17.9 million and the revenue for the first six months of the year totalled EUR 33.2 million. The Group’s net profit for the 2nd quarter of 2021 was EUR 1.25 million and the net profit for the first 6 months of the year was EUR 0.98 million. At the end of June, the share of the Group’s digital revenue was 53% of total revenue and 75% of media segment revenue. In the 2nd quarter of 2021, the consolidated revenue totalled EUR 17.9 million (2nd quarter 2020: EUR 13.9 million), increasing by 28%. The revenue growth is attributable to the online advertising market which has recovered well and has gained momentum on account of other types of media, demonstrating good growth in all Baltic States. Print advertising revenue continues to be under pressure and it has...

Accelerating order backlog in “New Cavotec”   On 5 March 2021, Cavotec communicated a decision to focus resources and make investments in the ports & maritime and industrial markets. As a consequence, a process was initiated to divest the Airports business. From the first quarter 2021, Cavotec reported the groups ports & maritime and industry businesses combined under the name New Cavotec. Airports is reported separately.   APRIL–JUNE 2021 NEW CAVOTEC Order backlog increased 19.0% compared to Q121 to EUR 77.4 million  Revenues decreased -13.7% to EUR 25.8 million (29.9)  EBIT amounted to EUR 0.9 million (1.1), corresponding to a margin of 3.5% (3.6%)  EBIT adjusted for growth investments amounted to EUR 1.3 million corresponding to a margin of 5.2%APRIL–JUNE 2021 TOTAL Order backlog increased 13.8% compared to Q121 to EUR 105.9 million  Revenues...

  Ad hoc announcement pursuant to Art. 53 LR    Lausanne,  30 July 20211st semester 2021: Adjusted revenue of CHF 491.0m, down 9.9% at constant exchange rates Compagnie Financière Tradition reported consolidated revenue of CHF 452.0m in the first semester 2021 compared with CHF 512.8m in same period in 2020, down 11.9% at current exchange rates. At constant exchange rates, consolidated revenue presented a decrease of 9.9%. For the same period, the Group’s consolidated adjusted* revenue was CHF 491.0m compared with CHF 558.0m in 2020, a decrease of 9.9% at constant exchange rates. The adjusted revenue from interdealer broking business (IDB) was down 9.8% at constant exchange rates while the forex trading business for retail investors in Japan (Non-IDB) presented a decrease of 13.8%. In the second quarter, consolidated revenue...

Lassila & Tikanoja plc Stock exchange release 30 July 2021 at 8:00 a.m. Changes in Lassila & Tikanoja’s Group Executive Board Senior Vice President, Facility Services Finland at Lassila & Tikanoja, Tuomas Mäkipeska, has resigned and will continue his career outside Lassila & Tikanoja. Antti Niitynpää (EMBA) has been appointed Senior Vice President, Facility Services Finland and a member of the Group Executive Board effective 30 July 2021 onwards. Currently, Niitynpää is Business Director, Cleaning Services, which is the largest service branch of Lassila & Tikanoja Facility Services Finland. At Lassila & Tikanoja, Niitynpää has previously held the position of Business Director in the Property Maintenance service branch and the position of Regional Director. He has also worked as Regional Director at ISS Finland,...

– Harnesses breakthrough AMD RDNA™ 2 gaming architecture, offering up to 15 percent higher performance on average in 1080p gaming across a range of popular titles compared to the competition – – Powerful blend of raytracing, compute and rasterized effects pairs with AMD FidelityFX Super Resolution upscaling technology and other advanced features to bring new levels of visual fidelity and high-framerate gaming to the mainstream – SANTA CLARA, Calif., July 29, 2021 (GLOBE NEWSWIRE) — AMD (NASDAQ: AMD) today announced the AMD Radeon™ RX 6600 XT graphics card, designed to deliver the ultimate high-framerate, high-fidelity and highly responsive 1080p gaming experience. The AMD Radeon RX 6600 XT graphics card is built on breakthrough AMD RDNA™ 2 architecture, the only gaming architecture that spans from next-generation desktop PCs, laptops...

Los Angeles, CA, July 29, 2021 (GLOBE NEWSWIRE) — Draganfly Inc. (Nasdaq: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), a drone manufacturer and systems developer, today announced the pricing of its underwritten public offering of 5,000,000 common shares of the Company at a public offering price of US$4.00 per share, for gross proceeds of US$20,000,000, before deducting underwriting discounts and offering expenses. Closing of the offering is expected to occur on August 3, 2021, subject to the satisfaction of customary closing conditions. In addition, the underwriters have been granted a 45-day over-allotment option following the closing date to purchase up to an additional 750,000 common shares from the Company. ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager...

CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced the pricing of its upsized initial public offering of 7,500,000 shares of Class A common stock at a public offering price of $15.00 per share, for total gross proceeds of $112.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Immuneering. All of the Class A common stock is being offered by Immuneering. The offering is expected to close on August 3, 2021, subject to customary closing conditions. In addition, Immuneering has granted the underwriters a 30-day option to purchase up to an additional 1,125,000...

ALISO VIEJO, Calif., July 29, 2021 (GLOBE NEWSWIRE) — RxSight, Inc., an ophthalmic medical device company, today announced the pricing of its initial public offering of 7,350,000 shares of common stock at a public offering price of $16.00 per share. The gross proceeds to RxSight® from the offering are expected to be $117.6 million, before deducting underwriting discounts and commissions and offering expenses. In addition, RxSight has granted the underwriters a 30-day option to purchase up to an additional 1,102,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. RxSight’s common stock is expected to begin trading on the Nasdaq Global Market on July 30, 2021, under the ticker symbol “RXST.” The offering is expected to close on August 3, 2021, subject to the satisfaction of...

Westport, CT, July 29, 2021 (GLOBE NEWSWIRE) — Williams Rowland Acquisition Corp. (the “Company”), a newly organized blank check company incorporated as a Delaware corporation and led by Co-Chief Executive Officers, David “Tiger” Williams and Jonathan Rowland, today announced the closing of its initial public offering of 20,000,000 units at an offering price of $10.00 per unit, with each unit consisting of one share of the common stock of the Company and one-half of one redeemable warrant. Each whole warrant will entitle the holder thereof to purchase one share of common stock at $11.50 per share. The Company has granted the underwriter a 45-day option to purchase up to 3,000,000 additional units at the initial public offering price to cover over-allotments, if any. The units began trading on July 27, 2021 on the New York Stock...

SHANGHAI, China, July 30, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has accepted its supplemental New Drug Application (sNDA) for toripalimab in combination with platinum-containing chemotherapy as the first-line treatment for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC). It is the fifth NDA submitted for toripalimab in China. The supplemental NDA is based on the JUPITER-06 study (Clinicaltrials.gov identifier: NCT03829969), which is a randomized, double-blind, placebo-controlled Phase III clinical study led by Professor Ruihua Xu from Sun Yat-sen...